Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Suggett, J. Mitchell, H. Schneider, R. Ali, M. Nagel (London, Canada). Delivery of dornase alfa via breath-actuated nebulizer: In-vitro measures of performance. Eur Respir J 2013; 42: Suppl. 57, 1186

Member's Comments

No comment yet.

Related content which might interest you: Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016 In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence? Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis Source: Eur Respir J 2011; 37: 806-812 Year: 2011 High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014